AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comSEP 242 min read$AMGN

Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks

Amgen (AMGN) rose 9.5% post-earnings, trading at $225.10. Myriad Genetics (MYGN) reported a 10.5% revenue decline, missing estimates, and fell 25.3% to $4.01. Novavax (NVAX) beat expectations with a 76.3% revenue drop but gained 36.7% to $10.53. Halozyme Therapeutics (HALO) grew revenue 47.7%, beating estimates, and rose 31.5% to $112.81.

Original reporting
finance.yahoo.com
Published Sep 24, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 11:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$AMGNBullishLow
01

Why it matters

Recap of earnings with no new fundamental data; price moves reflect market digestion of prior reports.

02

Market read

Provides a quick snapshot of therapeutic sector performance; useful for traders monitoring short‑term momentum.

03

What to watch

Potential upcoming pipeline updates or regulatory news could shift sentiment beyond the earnings recap.

Relevance 4/10Novelty 2/10Timing: post‑earnings recap

Background

The article summarizes Q2 earnings outcomes for four therapeutic companies, noting stock price reactions since the results were released weeks earlier.

Company-level read

Ticker impact

$AMGNBullishMedium confidence
Context

Stock up 9.5% since reporting Q2 results, trading at $225.10.

Expected impact

Potential short‑term upside as momentum continues.

Evidence & confidence

Move reflects market digest of already‑released earnings; no new fundamental data.

$MYGNBearishMedium confidence
Context

Stock down 25.3% since Q2 results, trading at $4.01 after revenue miss and weak guidance.

Expected impact

Further downside possible if guidance remains below expectations.

Evidence & confidence

Recap of already‑published earnings; no fresh information.

$NVAXBullishMedium confidence
Context

Stock up 36.7% since reporting, trading at $10.53 after revenue beat.

Expected impact

Short‑term upside may persist pending further guidance.

Evidence & confidence

Move reflects market reaction to known earnings numbers.

$HALOBullishMedium confidence
Context

Stock up 31.5% since reporting, trading at $112.81 after revenue surge and guidance raise.

Expected impact

Momentum could continue in the near term.

Evidence & confidence

Recap of already‑released earnings; no new data.

Market effects

Sector

Therapeutics sector shows mixed reactions to Q2 earnings, highlighting divergence in growth trajectories.

Regional

U.S. biotech stocks experience varied price moves, influencing broader health‑care index performance.

Global

Limited; primarily affects U.S. listed biotech equities.

Counterpoint

What could challenge this read

Despite strong moves, the underlying earnings were already known; price action may be short‑lived.

Key entities

  • Company
    Amgen

    Biotech giant with 9.5% stock rise post‑Q2 earnings.

  • Company
    Myriad Genetics

    Genetic testing firm with 25.3% stock decline after earnings miss.

  • Company
    Novavax

    Vaccine maker up 36.7% after revenue beat.

  • Company
    Halozyme Therapeutics

    Drug delivery specialist up 31.5% after strong Q2.

Read at source← All news

Related articles

SEP 24
$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.

nbcdfw.com3 min
SEP 23
$AMGNMedAI 9/10

First of Amgen’s Phase III Sjögren’s disease trials succeeds

Amgen's Phase III trial for dazodalibep in Sjögren's disease met its primary endpoint, showing a significant reduction in disease activity. The drug, acquired via Horizon Therapeutics, is being studied in another Phase III trial. No FDA-approved treatments exist for Sjögren's disease. Amgen plans to present detailed data at a medical meeting. Competitors like Novartis, RemeGen, and Johnson & Johnson are also developing treatments.

yahoo.com2 min
SEP 23
$AMGNHighAI 9/10

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen (AMGN) reported positive phase III study results for dazodalibep in systemic Sjögren's disease, showing significant improvement in disease activity. The company plans to present detailed data at an upcoming conference. AMGN shares have risen 27.9% year-to-date. Other pipeline candidates include olpasiran, xaluritamig, and daxdilimab.

finance.yahoo.com2 min
SEP 23
$AMGNMedAI 8/10

Canaccord reiterates Amgen stock Hold rating on pipeline win

Canaccord Genuity reiterated a Hold rating and $384 price target for Amgen (AMGN) after positive Phase 3 trial results for dazodalibep. The drug showed significant improvement in treating moderate-to-severe Sjogren’s disease. Amgen's stock trades at $410.24, with a P/E ratio of 25.46 and PEG ratio of 0.79. Analysts have mixed reactions, with some raising targets and others downgrading.

investing.com2 min
SEP 23
$AMGNHighAI 9/10

Amgen's Horizon buyout delivers Sjögren's disease win

Amgen's dazodalibep showed efficacy in a phase 3 trial for Sjögren's disease, meeting its primary endpoint. The drug is part of Amgen's $28B Horizon Pharma acquisition. Full data from a second trial is expected by year-end. No FDA-approved treatments exist for this autoimmune disorder.

pharmaphorum.com2 min